InspireMD Inc. (NSPR)
InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript
InspireMD, Inc. (NASDAQ:NSPR ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Marvin L. Slosman - President, CEO & Director Michael A.
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript
InspireMD, Inc. (NASDAQ:NSPR ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Webb Campbell – Gilmartin Group LLC Marvin Slosman – Chief Executive Officer Craig Shore – Chief Financial Officer Shane Gleason – Chief Commercial Officer Conference Call Participants Adam Maeder – Piper Sandler Frank Takkinen – Lake Street Capital Operator Good morning, and welcome to InspireMD's First Quarter 2025 Earnings Conference call. [Operator Instructions] We will facilitating a question-and-answer session towards the end of today's call.
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript
NSPR (NASDAQ:NSPR ) Q4 2024 Earnings Conference Call March 12, 2025 8:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Webb Campbell - IR, Gilmartin Group Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Richard Nesbitt - InspireMD Operator Hello and welcome to InspireMD's fourth quarter 2024 earnings conference call. [Operator instructions].
InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.
NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study
InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.
InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript
InspireMD, Inc. (NASDAQ:NSPR ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Chuck Padala - IR, Life Advisors Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Conference Call Participants Adam Maeder - Piper Sandler Operator Good day, everyone, and welcome to the InspireMD Third Quarter 2024 Earnings Call. Currently, all participants are in a listen-only mod e.
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.15 per share a year ago.
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent
NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis.
NSPR Stock Declines Despite PMA Application Submission for CGuard
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
